WebTherapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and to develop new approaches for overcoming resistance, we generated long-term cisplatin treated (LTT) UC cell lines, characterised their cisplatin response, and determined the expression of … WebThe protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively. To investigate the protein-binding properties of albumin with cisplatin, carboplatin and oxaliplatin, inductively coupl …
Targeted therapy for cisplatin‐resistant lung cancer via …
WebCisplatin-bound DNA impairs the normal functions of proteins involved in DNA repair and transcription. The nucleotide excision repair (NER) process typically removes bulky abnormalities caused by chemicals or … WebAug 19, 2005 · Cisplatin is a widely used anti-tumor agent for the treatment of testicular and ovarian cancers. Carboplatin is used extensively for small cell, non small cell lung cancer … pons bulbus
Cisplatin Protein Binding Partners and Their Relevance for …
WebMar 25, 2024 · Given that apoptosis resistance is one of the causes of the cisplatin resistance of tumor cells, our aim was to determine the relationship between RRS1 and cisplatin resistance in breast cancer cells. Here, we report that RRS1 is associated with cisplatin resistance in breast cancer cells. WebMay 15, 2016 · We summarize the structural features of known cisplatin-protein adducts. • Key characteristics of the cisplatin modes of binding to proteins are described. • … WebJun 13, 2005 · Protein binding Cisplatin does not undergo instantaneous and reversible binding to plasma protein that is characteristic of normal drug-protein binding. However, the platinum itself is capable of binding to plasma proteins, including albumin, transferrin, and gamma globulin. shaolin monks uk tour